Description du projet
Cibler les mécanismes de résistance aux médicaments anticancéreux
La résistance aux traitements anticancéreux représente le principal obstacle à la réussite du traitement à long terme et à la guérison des patients atteints de cancer. La société danoise Scandion Oncology développe un nouveau médicament (SCO‑101) qui cible efficacement plusieurs des mécanismes de résistance moléculaire les plus courants du cancer. SCO‑101 a passé avec succès quatre études cliniques de phase 1 chez des volontaires sains. L’objectif du projet SCANRESIST, financé par l’UE, est de mener des études de validation clinique chez des patients atteints d’un cancer résistant aux taxanes par le biais d’un essai clinique prospectif ouvert de phase 2, afin d’établir la preuve de concept de SCO‑101 en tant que modalité de traitement sûre et efficace. SCO‑101 représente un changement de paradigme en agissant par de multiples mécanismes pour interférer avec la résistance aux médicaments.
Objectif
Worldwide in 2018, cancer has been responsible for around 9.6 million deaths, and with a prediction of a further increase in incidence over the next years – which calls for urgent better treatment modalities to combat such deadly disease. Resistance to anticancer therapy is considered the main obstacle to successful clinical management of cancer patients. Scandion Oncology A/S (SCANDION) is a clinical-stage biotechnology company aimed to solve the anti-cancer drug resistance problem. We are developing a new drug, the SCO-101, which effectively targets some of the most common molecular resistance mechanisms in cancer. SCO-101 represent a paradigm shift in treatment of drug-resistant cancer, with multi mechanisms of actions in interfering with drug resistance. SCO-101 has previously passed four clinical phase I studies in healthy volunteers and proved to be a safe oral drug with very limited toxicity. The SCANRESIST project aims at performing clinical validation studies in taxane resistant breast cancer patients with open-labelled Phase II prospective clinical trial to establish SCO-101 Proof of Concept as a safe and efficient treatment modality.
Our business model is based on out-licensing SCO-101 to pharma players active in anti-cancer drugs – who will be responsible for the remaining clinical development and market launch. The Phase II clinical validation has been pointed as a critical step achieve a deal with big pharma partners/licensees, which we know are interested in novel drugs with novel MoA, and with well-designed and well-performed phase II studies with positive results. Thus, the project will not only open a large market for SCANDION as it will also allow us to position the company as a unique provider of a new generation of anti-cancer resistance drugs – continuing our path on developing other drugs to combat drug resistance in cancer, innovative trial designs, predictive biomarkers and biomarker endpoints.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
2100 KOBENHAVN
Danemark
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.